AiCure

Drug Sponsors

Forest Labs’ $1.46 billion acquisition of Furiex strengthens GI business

Tuesday, April 29, 2014 03:24 PM

By Ronald Rosenberg
CenterWatch Staff Writer

The pharmaceutical industry’s shopping spree for specific disease expertise or scale continued this week as Forest Laboratories announced plans to acquire Furiex Pharmaceuticals for up to $1.46 billion, including milestone payments.

More... »


Pfizer pursues AstraZeneca for potential $100 billion acquisition deal

Monday, April 28, 2014 02:15 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Having rejected two bids since January, Pfizer made its next move on Monday—a $99 billion stock and cash offer to acquire AstraZeneca, to create a single U.K.-based company that would become the world’s largest pharmaceutical company.

More... »

CenterWatch

Prestige Brands to acquire Insight Pharmaceuticals

Monday, April 28, 2014 01:11 PM

Prestige Brands Holdings has entered into a definitive agreement to acquire Insight Pharmaceuticals, a marketer and distributor of feminine care and other over-the-counter (OTC) healthcare products, for $750 million in cash. Prestige will acquire tax attributes with a present value of approximately $100 million, which results in an effective purchase price of approximately $650 million.

More... »

Zimmer Holdings to combine with Biomet for $13.35B

Friday, April 25, 2014 10:54 AM

Zimmer Holdings will acquire Biomet in a cash and stock transaction valued at approximately $13.35 billion, including the assumption of net debt. The transaction, which is subject to customary closing conditions and regulatory approvals, is expected to close in the first quarter of 2015.

More... »

Quintiles, Biogen Idec ink 5-year partnership

Thursday, April 24, 2014 01:04 PM

CRO Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement. The collaboration is designed to leverage the expertise and experience from both organizations to optimize Biogen Idec’s clinical development processes.

More... »

Allergan adopts one-year stockholder rights plan

Wednesday, April 23, 2014 02:16 PM

Irvine, Calif.-based Allergan has announced its board of directors has unanimously adopted a one-year stockholder rights plan effective April 22, and declared a dividend distribution of one preferred share purchase right on each outstanding share of the company's common stock.

More... »

Bio-Techne to acquire Shanghai PrimeGene Bio-Tech

Wednesday, April 16, 2014 01:40 PM

Techne, a developer, manufacturer and seller of biotechnology products and clinical controls, has announced that its R&D systems China subsidiary, a specialty manufacturer of biological products, has entered into an agreement to acquire 100% of Shanghai PrimeGene Bio-Tech.

More... »

BioAlliance Pharma, Topotarget to merge

Wednesday, April 16, 2014 01:18 PM

BioAlliance Pharma, an innovative company specialized in developing drugs within orphan oncology diseases, and Topotarget, a Scandinavian-based biopharmaceutical company, intend to merge to create an orphan oncology company with highly complementary pipelines of late-stage products addressing significant unmet medical needs.

More... »

Scripps Research Institute launches drug discovery initiative Scripps Advance

Monday, April 14, 2014 03:02 PM

The Scripps Research Institute (TSRI) has announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates. Scripps Advance's first collaborator in this new endeavor is the Johnson & Johnson Innovation Center in California.

More... »

NeoStem to acquire California Stem Cell

Monday, April 14, 2014 03:01 PM

NeoStem, a provider of emerging cellular therapy, has entered into a definitive agreement to acquire California Stem Cell (CSC), an Irvine, Calif.-based stem cell biotechnology company. NeoStem plans to initiate a pivotal phase III trial of Melapuldencel-T, an autologous melanoma initiating (stem) cell immune-based therapy intended to eliminate the tumor cells capable of causing disease recurrence.

More... »

Link to survey
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs